Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31530203 | 0.87 | CYP1A2 (0.58) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL1186530 | 0.85 | NPC1 (0.52) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL20590806 | 0.81 | NPC1 (0.54) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL22325530 | 0.81 | ALKBH1 (0.56) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL31530186 | 0.80 | CYP1A2 (0.51) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL31530274 | 0.80 | CYP1A2 (0.51) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL7016284 | 0.79 | CYP1A2 (0.55) | SMN1; SMN2MAPTCYP1A2CYP2C19CYP2D6 | |
| SCHEMBL27331702 | 0.78 | CYP1A2 (0.56) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL4639217 | 0.78 | MAOB (0.55) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL3235402 | 0.78 | NPC1 (0.72) | RAB9ASMN1; SMN2NPC1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654254-A4 | ANTIFUNGAL AZOLE DERIVATIVES HAVING A FLUOROVINYL MOIETY AND PROCESS FOR THE PREPARATION THEREOF | KOREA RES INST CHEM TECH (KR) | 2008-12-31 | — | — | EP | disclosed |
| US-20080027117-A1 | Antifungal Azole Derivatives Having a Fluorovinyl Moiety and Process for the Preparation Thereof | KOREA RESERACH INSTIITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-01-31 | — | — | US | disclosed |
| EP-1654254-A1 | ANTIFUNGAL AZOLE DERIVATIVES HAVING A FLUOROVINYL MOIETY AND PROCESS FOR THE PREPARATION THEREOF | Korea Research Institute of Chemical Technology (KR) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005014583-A1 | ANTIFUNGAL AZOLE DERIVATIVES HAVING A FLUOROVINYL MOIETY AND PROCESS FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027117-A1 | Antifungal Azole Derivatives Having a Fluorovinyl Moiety and Process for the Preparation Thereof | ERG28, CYP51A1, CYP4F8 | RAB9A 483/4885SMN1; SMN2 4676/4885NPC1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.